Alumni raised $1.45B in 2022 - Download Free Report Now

Mnemosyne Pharmaceuticals

First-in-class subunit-selective NMDA receptor modulators to treat neuropsychiatric diseases, specifically schizophrenia and Alzheimer\'s.

Start Trial Get Full Profile

There’s no risk. Start your trial today to see profiles of Mnemosyne Pharmaceuticals plus 5517 other startups.

Start Free 7 Day Trial Now

Learn More About Mnemosyne Pharmaceuticals

Technology/product details

Revenue projections

Capital raised to date

Growth strategy

Competing Startups


Companies We Work With